Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.90 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.90 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.90 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL5556979 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL7568616 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL4838648 | 1.00 | TSHR (0.90) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL8584098 | 0.95 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL3254191 | 0.95 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL2046433 | 0.95 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL2046430 | 0.95 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL3998225 | 0.95 | — | — | |
| Maleic Acid SCHEMBL20487516 | 0.95 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL6875 | 0.95 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9017698-A | — | — | None | — | — | JP | disclosed |
| US-7449480-B2 | Small molecule inhibitors of HER2 expression | BAYLOR COLLEGE OF MEDICINE (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1509226-A4 | SMALL MOLECULE INHIBITORS OF HER2 EXPRESSION | BAYLOR COLLEGE MEDICINE (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20070244076-A1 | Site and Rate Selective Prodrug Formulations of D609 with Antioxidant and Anticancer Activity | MUSC FOUNDATION RESEARCH DEVELOPMENT (US) | 2007-10-18 | — | — | US | disclosed |
| US-7019017-B2 | Small molecule inhibitors of HER2 expression | BAYLOR COLLEGE OF MEDICINE (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050288327-A1 | Small molecule inhibitors of HER2 expression | UESUGI MOTONARI | 2005-12-29 | — | — | US | disclosed |
| US-20050283007-A1 | Small molecule inhibitors of HER2 expression | BAYLOR COLLEGE OF MEDICINE | 2005-12-22 | — | — | US | disclosed |
| WO-2005074933-A1 | SMALL MOLECULE INHIBITORS OF HER2 EXPRESSION | BAYLOR COLLEGE OF MEDICINE (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005032492-A2 | SITE AND RATE SELECTIVE PRODRUG FORMULATIONS OF D609 WITH ANTIOXIDANT AND ANTICANCER ACTIVITY | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1509226-A2 | SMALL MOLECULE INHIBITORS OF HER2 EXPRESSION | Baylor College of Medicine (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-0663827-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-07-26 | — | — | EP | disclosed |
| WO-1995002607-A1 | 7-SUBSTITUTED-Δ4-6-AZASTEROID DERIVATIVES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1995002587-A1 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994021614-A1 | SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994014438-A1 | HYDANTOIN AND SUCCINIMIDE-SUBSTITUTED DERIVATIVES OF SPIROINDANYLCAMPHORSULFONYL OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994007496-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| WO-1993006092-A1 | PIPERAZINYL (SULFONYL)AMIDE DERIVATIVES OF CAMPHOR AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| US-5137904-A | Useful in the treatment of atherosclerosis and thrombosis | G. D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0486280-A2 | Piperidinylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1992-05-20 | — | — | EP | disclosed |
| WO-1992007821-A1 | DIASTEREOISOMERS OF BICYCLO-SUBSTITUTED PHENYLACETONITRILE DERIVATIVES | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050283007-A1 | Small molecule inhibitors of HER2 expression | ERBB2, ABCC2, SLC2A2 | KMT2A 3326/4885MEN1 2541/4885TSHR 311/4885 |
| US-20050288327-A1 | Small molecule inhibitors of HER2 expression | ERBB2, ABCC2, SLC2A2 | KMT2A 3326/4885MEN1 2541/4885TSHR 311/4885 |
| US-20070244076-A1 | Site and Rate Selective Prodrug Formulations of D609 with Antioxidant and Anticancer Activity | CDK9, CASP9, UGT1A9 | KMT2A 3516/4885MEN1 4018/4885TSHR 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.